These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 24195525

  • 1. Biology of ovarian cancer and trabectedin mechanism of action.
    Ray-Coquard I.
    Future Oncol; 2013 Dec; 9(12 Suppl):11-7. PubMed ID: 24195525
    [Abstract] [Full Text] [Related]

  • 2. Trabectedin mechanism of action and platinum resistance: molecular rationale.
    Ray-Coquard I.
    Future Oncol; 2017 Oct; 13(23s):17-21. PubMed ID: 29020822
    [Abstract] [Full Text] [Related]

  • 3. Trabectedin, a drug acting on both cancer cells and the tumour microenvironment.
    D'Incalci M, Badri N, Galmarini CM, Allavena P.
    Br J Cancer; 2014 Aug 12; 111(4):646-50. PubMed ID: 24755886
    [Abstract] [Full Text] [Related]

  • 4. Trabectedin mechanism of action: what's new?
    D'Incalci M.
    Future Oncol; 2013 Dec 12; 9(12 Suppl):5-10. PubMed ID: 24195524
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Trabectedin (ET-743/Yondelis) for treating soft tissue sarcomas and ovarian cancer].
    Gennigens C, Jerusalem G.
    Rev Med Liege; 2011 Dec 12; 66(7-8):452-5. PubMed ID: 21942081
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study.
    Monk BJ, Ghatage P, Parekh T, Henitz E, Knoblauch R, Matos-Pita AS, Nieto A, Park YC, Cheng PS, Li W, Favis R, Ricci D, Poveda A.
    Ann Oncol; 2015 May 12; 26(5):914-920. PubMed ID: 25722380
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Efficacy of trabectedin in platinum-sensitive-relapsed ovarian cancer: new data from the randomized OVA-301 study.
    Colombo N.
    Int J Gynecol Cancer; 2011 May 12; 21 Suppl 1():S12-6. PubMed ID: 21540666
    [Abstract] [Full Text] [Related]

  • 16. [Which patients with ovarian cancer shows the combination of trabectedin with pegylated liposomal doxorubicin].
    Khokhlova SV, Cherkasova MV, Orel NF, Limareva SV, Bazaeva IIa, Gorbunova VA.
    Vestn Ross Akad Med Nauk; 2013 May 12; (11):115-21. PubMed ID: 24640740
    [Abstract] [Full Text] [Related]

  • 17. Trabectedin: Supportive care strategies and safety profile.
    Jordan K, Jahn F, Jordan B, Kegel T, Müller-Tidow C, Rüssel J.
    Crit Rev Oncol Hematol; 2015 Jun 12; 94(3):279-90. PubMed ID: 25794812
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial.
    Lorusso D, Scambia G, Pignata S, Sorio R, Amadio G, Lepori S, Mosconi A, Pisano C, Mangili G, Maltese G, Sabbatini R, Artioli G, Gamucci T, Di Napoli M, Capoluongo E, Ludovini V, Raspagliesi F, Ferrandina G.
    Ann Oncol; 2016 Mar 12; 27(3):487-93. PubMed ID: 26681678
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.